Aptevo Therapeutics GAAP EPS of -$8.40

2 hours ago 1

Aptevo Therapeutics press release (NASDAQ:APVO): Q2 GAAP EPS of -$8.40.
Aptevo had cash and cash equivalents as of June 30, 2025, totaling $9.4 million. In Q2 2025, we raised $15.9M in gross proceeds from various equity offerings. Extending cash runway into late 4Q25

Recommended For You